Sarilumab Investigated to Treat COVID-19

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Sanofi LLC. News release: Sanofi and Regeneron begin global Kevzara (sarilumab) clinical trial program in patients with severe COVID-19. 2020 Mar 16.
Regeneron Pharmaceuticals. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 (NCT04315298). ClinicalTrails.gov. 2020 Mar 19.
Northwell Health. News release: Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials. 2020 Mar 20.

Last year, in Texas, they had no room to breathe. Texas has 301 designated trauma centers equipped to provide intensive care, 200 of which can care for at least four critically ill patients. In August 2021, 75 of these hospitals reported having no available beds in their intensive care units. Zero. This was due, in…

Sarilumab is now FDA approved to treat adults with polymyalgia rheumatica who have had an inadequate response to glucocorticoids or who cannot tolerate a glucocorticoid taper. This new indication is based on results from the multicenter, phase 3 SAPHYR trial.

The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…

Harder to Breathe: The Infrastructure Behind Medical Oxygen

FDA Approves Sarilumab for the Treatment of Adults with Glucocorticoid-Resistant PMR

New Findings for Polymyalgia Rheumatica & Osteoarthritis

Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients

Related Articles